October 12, 2015
Eli Lilly: Evacetrapib Phase 3 trial terminated
Eli Lilly and Company and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy.